• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023

by Lisa Nadal | Mar 16, 2023 | Past Events

Prof. Dr. Dario Neri (CEO and CSO), Dr. Covelli (CMO), Dr. Dakhel, Dr. De Luca, Dr. Cazzamalli, Dr. Galbiati, Dr. Puca, Sara Puglioli. Matilde Bocci, Giulia Rotta, Eleonora Prodi and Aureliano Zana will participate at the event. Moreover, the following abstracts have...

Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023

by Lisa Nadal | Mar 16, 2023 | Past Events

Prof. Dario Neri (CEO and CSO), and Emanuele Puca (Investor Relations) will participate at the event to present Philogen and its programs to the financial community.

Philogen to attend 19th EADO Congress on April 20-22, 2023

by Lisa Nadal | Mar 16, 2023 | Past Events

Dr. Covelli (CMO), Dr. Elia, Dr. Ravenni, and Dr. Nadal will participate at the event in Rome. The dermato-oncology team from St. Gallen will give a presentation entitled “Intralesional administration of L19IL2/L19TNF in difficult-to-treat BCC patients shows favorable...

Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)

by last | Nov 13, 2022 | Past Events

Philogen attends the SITC Annual Meeting in November 2022. Teresa Hemmerle, PhD, Senior Project Manager, to present an abstract entitled “Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against...

Philogen announces the publication of a new study in the European Journal of Nuclear Medicine and Molecular Imaging

by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific

The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details

Philogen’s management team held a webinar on 29 September 2022 at 16:00 CEST

by last | Sep 28, 2022 | 2022, Past Events

Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of 30 June 2022. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief...
« Older Entries

Recent Posts

  • Philochem to attend the 71st American Society for Mass Spectrometry Conference on June 4-8, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023
  • Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch